PomDoctor Securities Class Action Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy POM?
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, failing to disclose a fraudulent stock promotion scheme involving social media, which led to manipulated stock prices and affected investor decisions.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure proper representation in the lawsuit and avoid inexperienced intermediaries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy POM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on POM
About POM
PomDoctor Ltd is a holding company principally engaged in operating a online medical services platform for chronic diseases. The Company operates its businesses through two segments. The Internet Hospital segment mainly engaged in providing online follow-up consultations and online prescription renewal service to customers and also sells prescription to customers through the website and apps. The Pharmaceutical Supply Chain segment mainly engaged in pharmacy retail sales and wholesale. The Company mainly operates its businesses in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PomDoctor Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, failing to disclose a fraudulent stock promotion scheme involving social media, which led to manipulated stock prices and affected investor decisions.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure proper representation in the lawsuit and avoid inexperienced intermediaries.
See More
PomDoctor and Inovio Face Class Action Lawsuits
- PomDoctor Class Action: PomDoctor, Ltd. (NASDAQ:POM) faces a class action lawsuit for the period from October 9, 2025, to December 11, 2025, alleging that the company failed to disclose a fraudulent stock promotion scheme involving social media, which has led to significant investor losses and could adversely affect the company's reputation and stock price.
- Insider Trading Allegations: The lawsuit claims that insiders used offshore accounts to facilitate stock dumping, and the failure to disclose this information has severely damaged the company's image among investors, potentially complicating future financing efforts.
- Inovio's Regulatory Challenges: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is facing a class action lawsuit for the period from October 10, 2023, to December 26, 2025, alleging that the company did not disclose deficiencies in the manufacturing of its CELLECTRA device, which jeopardizes the prospects of its Biologics License Application, leading to a decline in investor confidence.
- FDA Review Impact: Although Inovio's Biologics License Application was accepted by the FDA on December 29, 2025, the company failed to provide adequate information for accelerated approval, resulting in a 24.45% drop in stock price, reflecting market concerns about its future commercial prospects.
See More
PomDoctor Investors Class Action Notice Issued
- Class Action Notice: The Portnoy Law Firm has advised PomDoctor Ltd. investors of a class action for those who purchased securities between October 9 and December 11, 2025, with a deadline of April 6, 2026, to file a lead plaintiff motion to protect their legal rights.
- Fraud Allegations: The lawsuit alleges that PomDoctor and its executives violated federal securities laws by making false and misleading statements and failing to disclose the company's involvement in a fraudulent stock promotion scheme driven by social media misinformation and impersonated financial professionals.
- Stock Price Plunge: PomDoctor's share price experienced a significant decline from approximately $0.50 per share on December 10, 2025, to about $0.38 per share on December 11, representing a 24% drop in a single trading session, amid heightened volatility and investor concerns regarding the company's financial performance and valuation.
- Legal Support and Recovery: The Portnoy Law Firm offers complimentary case evaluations to assist investors in pursuing claims for losses due to corporate wrongdoing, with the founding partner having recovered over $5.5 billion for aggrieved investors in the past.
See More
Reminder of Class Action Lawsuit for PomDoctor Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme during the class period, utilizing social media to spread misinformation, which misled investors and affected their judgment regarding the company's business and prospects.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
- Investor Advisory: Investors are advised to be cautious when selecting legal counsel, as many firms issuing notices lack actual litigation experience; Rosen Law Firm emphasizes the importance of choosing a firm with a proven track record in leadership roles to ensure optimal representation in class actions.
See More
Pomdoctor Investors Encouraged to Seek Legal Options
- Legal Claim Investigation: Faruq & Faruqi LLP is investigating potential claims against Pomdoctor, specifically targeting investors who purchased securities between October 9, 2025, and December 11, 2025, aiming to provide legal support for affected investors.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors in Pomdoctor should note that the deadline to seek the role of lead plaintiff in a federal securities class action is April 13, 2026, making this date critical for potential claims.
- Securities Law Firm Background: Faruq & Faruqi is a leading national securities law firm focused on providing legal support to investors, ensuring their rights are protected in the securities market.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during this period, involving fraudulent stock promotion schemes and insider trading through offshore accounts, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019, demonstrating its strong capabilities in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success rather than those acting merely as intermediaries, ensuring they receive the best representation and support in the class action.
See More
PomDoctor Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, failing to disclose a fraudulent stock promotion scheme involving social media, which led to manipulated stock prices and affected investor decisions.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure proper representation in the lawsuit and avoid inexperienced intermediaries.
See More
PomDoctor and Inovio Face Class Action Lawsuits
- PomDoctor Class Action: PomDoctor, Ltd. (NASDAQ:POM) faces a class action lawsuit for the period from October 9, 2025, to December 11, 2025, alleging that the company failed to disclose a fraudulent stock promotion scheme involving social media, which has led to significant investor losses and could adversely affect the company's reputation and stock price.
- Insider Trading Allegations: The lawsuit claims that insiders used offshore accounts to facilitate stock dumping, and the failure to disclose this information has severely damaged the company's image among investors, potentially complicating future financing efforts.
- Inovio's Regulatory Challenges: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is facing a class action lawsuit for the period from October 10, 2023, to December 26, 2025, alleging that the company did not disclose deficiencies in the manufacturing of its CELLECTRA device, which jeopardizes the prospects of its Biologics License Application, leading to a decline in investor confidence.
- FDA Review Impact: Although Inovio's Biologics License Application was accepted by the FDA on December 29, 2025, the company failed to provide adequate information for accelerated approval, resulting in a 24.45% drop in stock price, reflecting market concerns about its future commercial prospects.
See More
PomDoctor Investors Class Action Notice Issued
- Class Action Notice: The Portnoy Law Firm has advised PomDoctor Ltd. investors of a class action for those who purchased securities between October 9 and December 11, 2025, with a deadline of April 6, 2026, to file a lead plaintiff motion to protect their legal rights.
- Fraud Allegations: The lawsuit alleges that PomDoctor and its executives violated federal securities laws by making false and misleading statements and failing to disclose the company's involvement in a fraudulent stock promotion scheme driven by social media misinformation and impersonated financial professionals.
- Stock Price Plunge: PomDoctor's share price experienced a significant decline from approximately $0.50 per share on December 10, 2025, to about $0.38 per share on December 11, representing a 24% drop in a single trading session, amid heightened volatility and investor concerns regarding the company's financial performance and valuation.
- Legal Support and Recovery: The Portnoy Law Firm offers complimentary case evaluations to assist investors in pursuing claims for losses due to corporate wrongdoing, with the founding partner having recovered over $5.5 billion for aggrieved investors in the past.
See More
Reminder of Class Action Lawsuit for PomDoctor Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme during the class period, utilizing social media to spread misinformation, which misled investors and affected their judgment regarding the company's business and prospects.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
- Investor Advisory: Investors are advised to be cautious when selecting legal counsel, as many firms issuing notices lack actual litigation experience; Rosen Law Firm emphasizes the importance of choosing a firm with a proven track record in leadership roles to ensure optimal representation in class actions.
See More
Pomdoctor Investors Encouraged to Seek Legal Options
- Legal Claim Investigation: Faruq & Faruqi LLP is investigating potential claims against Pomdoctor, specifically targeting investors who purchased securities between October 9, 2025, and December 11, 2025, aiming to provide legal support for affected investors.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors in Pomdoctor should note that the deadline to seek the role of lead plaintiff in a federal securities class action is April 13, 2026, making this date critical for potential claims.
- Securities Law Firm Background: Faruq & Faruqi is a leading national securities law firm focused on providing legal support to investors, ensuring their rights are protected in the securities market.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during this period, involving fraudulent stock promotion schemes and insider trading through offshore accounts, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019, demonstrating its strong capabilities in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success rather than those acting merely as intermediaries, ensuring they receive the best representation and support in the class action.
See More
